COVID-19 vaccine concerns of health care providers and ancillary staff

por Lewin, Bruno J., Bronstein, David, Tubert, Julia E., Chang, John, Luo, Yi X., Choi, Kristen R., Munoz-Plaza, Corrine, Rondinelli, June L., Bruxvoort, Katia
Publicado 2022

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study

por Bruxvoort, Katia J., Sy, Lina S., Qian, Lei, Ackerson, Bradley K., Luo, Yi, Lee, Gina S., Tian, Yun, Florea, Ana, Takhar, Harpreet S., Tubert, Julia E., Talarico, Carla A., Tseng, Hung Fu
Publicado 2021

Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study

por Florea, Ana, Sy, Lina S., Luo, Yi, Qian, Lei, Bruxvoort, Katia J., Ackerson, Bradley K., Lee, Gina S., Ku, Jennifer H., Tubert, Julia E., Tian, Yun, Talarico, Carla A., Tseng, Hung Fu
Publicado 2022

Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study

por Ku, Jennifer H., Sy, Lina S., Qian, Lei, Ackerson, Bradley K., Luo, Yi, Tubert, Julia E., Lee, Gina S., Florea, Ana, Bruxvoort, Katia J., Talarico, Carla A., Qiu, Sijia, Tian, Yun, Tseng, Hung Fu
Publicado 2023

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults

por Florea, Ana, Sy, Lina S, Qian, Lei, Ackerson, Bradley K, Luo, Yi, Tubert, Julia E, Lee, Gina S, Ku, Jennifer H, Bruxvoort, Katia J, Talarico, Carla A, Qiu, Sijia, Tian, Yun, Tseng, Hung Fu
Publicado 2022

Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study

por Ku, Jennifer H., Sy, Lina S., Qian, Lei, Ackerson, Bradley K., Luo, Yi, Tubert, Julia E., Lee, Gina S., Florea, Ana, Bruxvoort, Katia J., Xie, Fagen, Qiu, Sijia, Chavers, Scott, Talarico, Carla A., Tseng, Hung Fu
Publicado 2023

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

por Bruxvoort, Katia J, Sy, Lina S, Qian, Lei, Ackerson, Bradley K, Luo, Yi, Lee, Gina S, Tian, Yun, Florea, Ana, Aragones, Michael, Tubert, Julia E, Takhar, Harpreet S, Ku, Jennifer H, Paila, Yamuna D, Talarico, Carla A, Tseng, Hung Fu
Publicado 2021

Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

por Tseng, Hung Fu, Ackerson, Bradley K., Luo, Yi, Sy, Lina S., Talarico, Carla A., Tian, Yun, Bruxvoort, Katia J., Tubert, Julia E., Florea, Ana, Ku, Jennifer H., Lee, Gina S., Choi, Soon Kyu, Takhar, Harpreet S., Aragones, Michael, Qian, Lei
Publicado 2022

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

por Tseng, Hung Fu, Ackerson, Bradley K., Luo, Yi, Sy, Lina S., Talarico, Carla A., Tian, Yun, Bruxvoort, Katia J., Tubert, Julia E., Florea, Ana, Ku, Jennifer H., Lee, Gina S., Choi, Soon Kyu, Takhar, Harpreet S., Aragones, Michael, Qian, Lei
Publicado 2022

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5

por Tseng, Hung Fu, Ackerson, Bradley K., Bruxvoort, Katia J., Sy, Lina S., Tubert, Julia E., Lee, Gina S., Ku, Jennifer H., Florea, Ana, Luo, Yi, Qiu, Sijia, Choi, Soon Kyu, Takhar, Harpreet S., Aragones, Michael, Paila, Yamuna D., Chavers, Scott, Talarico, Carla A., Qian, Lei
Publicado 2023

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States

por Tseng, Hung Fu, Ackerson, Bradley K., Sy, Lina S., Tubert, Julia E., Luo, Yi, Qiu, Sijia, Lee, Gina S., Bruxvoort, Katia J., Ku, Jennifer H., Florea, Ana, Takhar, Harpreet S., Bathala, Radha, Zhou, Cindy Ke, Esposito, Daina B., Marks, Morgan A., Anderson, Evan J., Talarico, Carla A., Qian, Lei
Publicado 2023